Search Results - "Papneja, N"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    A review of cancer immunotherapy: from the past, to the present, to the future by Esfahani, K, Roudaia, L, Buhlaiga, N, Del Rincon, S V, Papneja, N, Miller, Jr, W H

    Published in Current oncology (Toronto) (01-04-2020)
    “…Compared with previous standards of care (including chemotherapy, radiotherapy, and surgery), cancer immunotherapy has brought significant improvements for…”
    Get full text
    Journal Article
  2. 2
  3. 3

    701P - Outcomes of first-line FOLFIRINOX (FFX) versus gemcitabine and nab-paclitaxel (GN) in patients with advanced pancreatic cancer: Multi-Institutional Canadian sites experience by Papneja, N., Ahmed, S., Mondal, P., Barrera, I., Papneja, A., Batist, G., Kavan, P.

    Published in Annals of oncology (01-10-2019)
    “…FOLFIRINOX (FFX) and Gemcitabine with nab-Paclitaxel (GN) are both proven to be superior to Gemcitabine in first line treatment for advanced pancreatic cancer…”
    Get full text
    Journal Article
  4. 4

    701POutcomes of first-line FOLFIRINOX (FFX) versus gemcitabine and nab-paclitaxel (GN) in patients with advanced pancreatic cancer: Multi-Institutional Canadian sites experience by Papneja, N, Ahmed, S, Mondal, P, Barrera, I, Papneja, A, Batist, G, Kavan, P

    Published in Annals of oncology (01-10-2019)
    “…Abstract Background FOLFIRINOX (FFX) and Gemcitabine with nab-Paclitaxel (GN) are both proven to be superior to Gemcitabine in first line treatment for…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7